Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly Incretin

Tests eloralintide against placebo in adults with obesity already taking a weekly incretin.

Key facts

Who runs it
Eli Lilly and Company
Where
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou, Jinan, Luoyang Shi, Luzhou, Nanchang, Nanjing, Ningbo, Shanghai, Wenzhou, Wuhan, and Xianyang, ChinaSee the 22 sitesAlso in 13 other countries, 164 sites
Trial code
Registry title
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Status
Recruiting
Phase
Phase 3
People taking part
900 people, planned
Started
10 Feb 2026
Expected to end
Jul 2028
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eloralintide
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity or overweight who are already on a stable weekly incretin treatment. Some may also have type 2 diabetes.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Persistent obesity or overweight: BMI ≥30 kg/m2, or ≥27 kg/m2 with at least one obesity-related condition (high blood pressure, abnormal blood fats, sleep apnea, heart or blood vessel disease, or type 2 diabetes).
Earlier treatment
Must be on stable incretin therapy at screening. Must not have taken DPP-4 inhibitors, amylin analogs or insulin within 90 days before screening.

Main reasons for not taking part

  • Prior or planned surgery for obesity (some procedures allowed if done more than 1 year before screening)
  • Prior or planned endoscopic procedure or device-based obesity treatment (prior device allowed if removed more than 6 months before screening)
  • Type 1 diabetes
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
  • History of New York Heart Association Class IV congestive heart failure

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Are on stable incretin therapy at screening
  • With persistent obesity or overweight defined as:; ≥30 kg/m2 OR; ≥27 kg/m2 with at least one existing obesity related complication at screening:; hypertension; dyslipidemia; obstructive sleep apnea; cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or; type 2 diabetes
  • Have a stable body weight (<5% body weight change) at screening

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have taken any of the following antihyperglycemic medications within 90 days before screening:; dipeptidyl peptidase-4 (DPP-4) inhibitors; amylin analogs; insulin
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have type 1 diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where in China

Also in 13 other countries, 164 sites

  • The First Hospital of Jilin UniversityChangchun, ChinaContact: Guixia Wang (principal investigator)Not yet recruiting
  • The Second Hospital of Jilin UniversityChangchun, ChinaContact: Hanqing Cai (principal investigator)Taking people
  • The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Xia Li (principal investigator)Taking people
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Limin Tian (principal investigator)Taking people
  • West China Hospital，Sichuan UniversityChengdu, ChinaContact: zhenmei an (principal investigator)Taking people
  • 2nd Affiliated Hospital Chongqing Medical UniversiChongqing, ChinaContact: Dongfang Liu (principal investigator)Not yet recruiting
  • Zhujiang HospitalGuangzhou, ChinaContact: Jia Sun (principal investigator)Taking people
  • The Affiliated Hospital of Guizhou Medical UniversityGuiyang, ChinaContact: Miao Zhang (principal investigator)Taking people
  • The Second People's Hospital of HefeiHefei, ChinaContact: Jun Ye (principal investigator)Taking people
  • Huzhou Central HospitalHuzhou, ChinaContact: Shunbin Li (principal investigator)Taking people
  • Jinan Central HospitalJinan, ChinaContact: Nianrong Mi (principal investigator)Not yet recruiting
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaContact: Hongwei Jiang (principal investigator)Taking people
  • Affiliated Hospital of Luzhou Medical CollegeLuzhou, ChinaContact: Qin Wan (principal investigator)Taking people
  • Jiangxi Provincial People's HospitalNanchang, ChinaContact: Zongyou Cheng (principal investigator)Taking people
  • Nanjing First HospitalNanjing, ChinaContact: Qian Li (principal investigator)Taking people
  • The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaContact: Yibing Lu (principal investigator)Taking people
  • Zhongda Hospital Southeast UniversityNanjing, ChinaContact: Ling Li (principal investigator)Taking people
  • Ningbo First HospitalNingbo, ChinaContact: Li Li (principal investigator)Taking people
  • Zhongshan Hospital,Fudan UniversityShanghai, ChinaContact: Xiaoying Li (principal investigator)Not yet recruiting
  • The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Chaoming Wu (principal investigator)Not yet recruiting
  • The Central Hospital of WuhanWuhan, ChinaContact: Zhongjing Wang (principal investigator)Taking people
  • Xianyang Hospital of Yan'an UniversityXianyang, ChinaContact: Fang Wang (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.

Read full original descriptionShow less

Participation in the study will last about 80 weeks.

The 5 groups in the trial

  • Eloralintide Dose 1Treatment being tested

    Participants will receive eloralintide subcutaneously (SC)

    Treatment: Eloralintide

  • Eloralintide Dose 2Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Eloralintide Dose 3Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Eloralintide Dose 4Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Plain-language title
Eloralintide for Adults With Obesity Who Still Carry Excess Weight on a Weekly IncretinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026